Repros’ IND for the Commencement of Phase III Studies of Proellex ...Business Wire (press release), CA - Feb 22, 2008Our lead drug, Proellex®, is a selective blocker of the progesterone receptor and is targeted for the treatment of uterine fibroids, endometriosis and ...
RPRX
No comments:
Post a Comment